000			nab a22 7a 4500
999			_c16942 _d16942
003			PC16942
005			20220712115007.0
008			220712b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_91233 _aHernández Hernández, Felipe _eCardiología
245	0	0	_aDual Antiplatelet Therapy for 6 Months vs 12 Months After New-generation Drug-eluting Stent Implantation: Matched Analysis of ESTROFA-DAPT and ESTROFA-2. _h[artículo]
260			_bRevista española de cardiología (English ed.), _c2015
300			_a68(10):838-45.
500			_aFormato Vancouver: De la Torre Hernández JM, Oteo Domínguez JF, Hernández F, García Camarero T, Abdul-Jawad Altisent O, Rivero Crespo F et al; ESTROFA-DAPT and ESTROFA-2 study groups. Dual Antiplatelet Therapy for 6 Months vs 12 Months After New-generation Drug-eluting Stent Implantation: Matched Analysis of ESTROFA-DAPT and ESTROFA-2. Rev Esp Cardiol (Engl Ed). 2015 Oct;68(10):838-45.
501			_aPMID: 26072146
504			_aContiene 25 referencias
520			_aIntroduction and objectives: The recommendation for dual antiplatelet therapy following drug-eluting stent implantation ranges from 6 months to 12 months or beyond. Recent trials have suggested the safety of a 6-month dual antiplatelet therapy regimen, yet certain caveats to these studies limit the applicability of this shorter duration dual antiplatelet therapy strategy in real world settings. Methods: A registry was constructed with consecutive recruitment of patients undergoing new-generation drug-eluting stent implantation and prescribed 6 months of dual antiplatelet therapy. Propensity score matching was undertaken with a historical cohort of patients treated with second-generation drug-eluting stents who received 12 months of dual antiplatelet therapy from the ESTROFA-2 registry. The sample size was calculated using a noninferiority basis and the primary endpoint was the combination of cardiac death, myocardial infarction, revascularization, or major bleeding at 12 months. Results: The analysis included 1286 patients in each group, with no significant differences in baseline characteristics. The primary endpoint occurred in 5.0% and 6.6% in the 6-month and 12-month groups, respectively (P = .001 for noninferiority). The incidence of definite or probable stent thrombosis was 0.5% and 0.7% in the 6-month and 12-month groups, respectively (P = .4). Major bleeding events were lower in the 6-month group than in the 12-month group (0.8% vs 1.4%; P = .2) CONCLUSIONS: In selected patients in this large multicenter study, the safety and efficacy of a 6-month dual antiplatelet therapy regimen after implantation of new-generation drug-eluting stents appeared to be noninferior to those of a 12-month dual antiplatelet therapy regimen.
710			_9119 _aServicio de Cardiología
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc16942.pdf _ySolicitar documento
942			_2ddc _cART _n0